InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

AUGMENT-101: This phase I/II study is assessing the best dose level, safety and effectiveness of a new drug (SNDX-5613) in people with acute leukaemiaA Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Clinical summary

Summary

This study has two phases. Phase 1 (Dose escalation), will consist of six sequential cohorts of escalating dose levels of SNDX-5613 (administered orally) to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). Participants will be enrolled in one of six dose-escalation arms. Arm A: participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole. Arm B: Participants receiving any strong CYP3A4 inhibitors for antifungal prophylaxis. Arm C: participants receiving SNDX-5613 and cobicistat. Arm D: participants receiving fluconazole for antifungal prophylaxis. Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers. Arm F: participants receiving isavuconazole for antifungal prophylaxis. Phase 2 of the study involves participants being enrolled in 3 disease-specific expansion cohorts.

Age

People0+

Phase

I/II

Trial Acronym

AUGMENT-101

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Syndax Pharmaceuticals

Scientific Title

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You are able to swallow medication by mouth.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more